Cell Reports (May 2020)
Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma
- Deepak Bararia,
- Johannes A. Hildebrand,
- Sebastian Stolz,
- Sarah Haebe,
- Stefan Alig,
- Christopher P. Trevisani,
- Francisco Osorio-Barrios,
- Michael D. Bartoschek,
- Michael Mentz,
- Alessandro Pastore,
- Erik Gaitzsch,
- Michael Heide,
- Vindi Jurinovic,
- Katharina Rautter,
- Jay Gunawardana,
- Muhammed B. Sabdia,
- Monika Szczepanowski,
- Julia Richter,
- Wolfram Klapper,
- Abner Louissaint, Jr.,
- Christina Ludwig,
- Sebastian Bultmann,
- Heinrich Leonhardt,
- Sebastian Eustermann,
- Karl-Peter Hopfner,
- Wolfgang Hiddemann,
- Michael von Bergwelt-Baildon,
- Christian Steidl,
- Robert Kridel,
- Joshua W.D. Tobin,
- Maher K. Gandhi,
- David M. Weinstock,
- Marc Schmidt-Supprian,
- Menyhárt B. Sárosi,
- Martina Rudelius,
- Verena Passerini,
- Josef Mautner,
- Oliver Weigert
Affiliations
- Deepak Bararia
- Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden-Wuerttemberg 69120, Germany
- Johannes A. Hildebrand
- Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden-Wuerttemberg 69120, Germany
- Sebastian Stolz
- Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany
- Sarah Haebe
- Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany
- Stefan Alig
- Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany
- Christopher P. Trevisani
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
- Francisco Osorio-Barrios
- Institute of Experimental Hematology, TranslaTUM, Klinikum rechts der Isar, Technical University of Munich, Munich, Bavaria 81675, Germany
- Michael D. Bartoschek
- Department of Biology II, Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany
- Michael Mentz
- Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany
- Alessandro Pastore
- Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Erik Gaitzsch
- Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden-Wuerttemberg 69120, Germany
- Michael Heide
- Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden-Wuerttemberg 69120, Germany
- Vindi Jurinovic
- Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; Institute for Medical Information Processing, Biometry, and Epidemiology, Munich, Bavaria 81377, Germany
- Katharina Rautter
- Immunoanalytics: Research Group Tissue Control of Immunocytes & Core Facility, German Research Center for Environmental Health, Helmholtz Zentrum München, Munich, Bavaria 81377, Germany
- Jay Gunawardana
- Blood Cancer Research Group, Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD 4101, Australia
- Muhammed B. Sabdia
- Blood Cancer Research Group, Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD 4101, Australia
- Monika Szczepanowski
- Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein 24105, Germany
- Julia Richter
- Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein 24105, Germany
- Wolfram Klapper
- Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein 24105, Germany
- Abner Louissaint, Jr.
- Massachusetts General Hospital, Department of Pathology, Boston, MA 02114, USA
- Christina Ludwig
- Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS), Technical University of Munich, Munich, Bavaria 85354, Germany
- Sebastian Bultmann
- Department of Biology II, Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany
- Heinrich Leonhardt
- Department of Biology II, Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany
- Sebastian Eustermann
- Gene Center, Ludwig-Maximilians-University, Munich, Bavaria 81377, Germany
- Karl-Peter Hopfner
- Gene Center, Ludwig-Maximilians-University, Munich, Bavaria 81377, Germany
- Wolfgang Hiddemann
- Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden-Wuerttemberg 69120, Germany
- Michael von Bergwelt-Baildon
- Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden-Wuerttemberg 69120, Germany
- Christian Steidl
- Center for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC V5Z 1L3, Canada
- Robert Kridel
- Center for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC V5Z 1L3, Canada
- Joshua W.D. Tobin
- Blood Cancer Research Group, Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD 4101, Australia
- Maher K. Gandhi
- Blood Cancer Research Group, Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD 4101, Australia
- David M. Weinstock
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
- Marc Schmidt-Supprian
- German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; Institute of Experimental Hematology, TranslaTUM, Klinikum rechts der Isar, Technical University of Munich, Munich, Bavaria 81675, Germany
- Menyhárt B. Sárosi
- Institute of Inorganic Chemistry, Faculty of Chemistry and Mineralogy, Leipzig University, Leipzig, Saxony 04103, Germany
- Martina Rudelius
- Institute of Pathology, Ludwig-Maximilians-University (LMU), Munich, Bavaria 80337, Germany
- Verena Passerini
- Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden-Wuerttemberg 69120, Germany
- Josef Mautner
- Helmholtz Zentrum München & Techniqual University of Munich, Munich, Bavaria 81377, Germany
- Oliver Weigert
- Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden-Wuerttemberg 69120, Germany; Corresponding author
- Journal volume & issue
-
Vol. 31,
no. 5
Abstract
Summary: Tumor cells orchestrate their microenvironment. Here, we provide biochemical, structural, functional, and clinical evidence that Cathepsin S (CTSS) alterations induce a tumor-promoting immune microenvironment in follicular lymphoma (FL). We found CTSS mutations at Y132 in 6% of FL (19/305). Another 13% (37/286) had CTSS amplification, which was associated with higher CTSS expression. CTSS Y132 mutations lead to accelerated autocatalytic conversion from an enzymatically inactive profrom to active CTSS and increased substrate cleavage, including CD74, which regulates major histocompatibility complex class II (MHC class II)-restricted antigen presentation. Lymphoma cells with hyperactive CTSS more efficiently activated antigen-specific CD4+ T cells in vitro. Tumors with hyperactive CTSS showed increased CD4+ T cell infiltration and proinflammatory cytokine perturbation in a mouse model and in human FLs. In mice, this CTSS-induced immune microenvironment promoted tumor growth. Clinically, patients with CTSS-hyperactive FL had better treatment outcomes with standard immunochemotherapies, indicating that these immunosuppressive regimens target both the lymphoma cells and the tumor-promoting immune microenvironment.